Our competitive ambition and success is based on scientific progress, continuous improvement with robust quality control and our business partnership reliability worldwide.About Rigvir Group
Together with our partners, we collaborate to develop first-in-class virotherapy medicines that are set to remodel the way cancer is understood and treated.Explore
To invent, develop and provide access to advanced biotechnological products that transform the treatment paradigm in oncology - fight cancer effectively and are safe and harmless for patient lives.
First genetically non-modified virus
One of the fastest growing biotech companies of the Northern Europe
Proven in clinical practice for more than 10 years
The story of Rigvir Group was started by professor Aina Muceniece, a pioneer scientist who looked into the future and unlocked the potential of oncolytic virotherapy for cancer patients.Explore